![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, November 09, 2005 4:46:03 AM
Peter Kang, Forbes.com, 10.31.05, 7:00 AM ET
Amylin Pharmaceuticals (nasdaq: AMLN - news - people ) pulled back from new all-time highs last week, after the specialty drugmaker announced third-quarter results last Wednesday. The company reported a loss of 65 cents per share on revenue of $25.9 million, compared with a consensus estimate for a loss of 57 cents per share on revenue of $30.7 million. Morgan Stanley raised the price target on the stock to $39 from $29 and has high hopes for Amylin's exenatide LAR, an experimental diabetes treatment analyst Steven Harr says has "mega-blockbuster potential." Harr expects "strongly positive" midstage trial results for exenatide LAR used in combination with a relatively new class of drugs known as peroxisome proliferator-activated receptors (PPARs). The stock closed Friday down 7% for the week, but shares have gained 43% year-to-date.
http://www.forbes.com/markets/2005/10/28/merck-pfizer-earnings-cx_pk_1028roundupbiotech.html?partner...
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM